Ultrafast-Acting Insulins: State of the Art
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Optimal coverage of prandial insulin requirements remains an elusive goal. The invention of rapid-acting insulin analogs (RAIAs) was a big step forward in reducing postprandial glycemic excursions in patients with diabetes in comparison with using regular human insulin; however, even with these, the physiological situation cannot be adequately mimicked. Developing ultrafast-acting insulins (UFIs)—showing an even more rapid onset of action and a shorter duration of action after subcutaneous (SC) administration—is another step forward in achieving this goal. The need for UFIs has been gradually recognized over the years, and subsequently, a number of different approaches to cover this need are in clinical development. A rapid increase in circulating insulin levels can be achieved by different measures: Modification of the primary structure of insulin molecule (as we know from RAIAs), addition of excipients that enhance the appearance in the monomeric state post-injection, or addition of enzymes that enable more free spreading of the insulin molecules in the SC tissue. Other measures to increase the insulin absorption rate increase the local blood flow nearby the insulin depot in the SC tissue, injecting the insulin intradermally or applying via another route, e.g., the lung. The development of these approaches is in different stages, from quite early stages to nearing market authorization. In time, daily practice will show if the introduction of UFIs will fulfill their clinical promise. In this review, the basic idea for UFIs will be presented and the different approaches will be briefly characterized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461
Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects.
Polonsky, K. S., Given, B. D., & Van Cauter, E. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113339 · Cited by 763
Glucose Variability; Does It Matter?
Siegelaar, S. E., Holleman, F., Hoekstra, J. B. L., & DeVries, J. H. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0021 · Cited by 409
Supersaxo, A., Hein, W. R., & Steffen, H. (1990) · Pharmaceutical Research · doi:10.1023/a:1015880819328 · Cited by 386
Raz, I., Wilson, P. W. F., Strojek, K., Kowalska, I., Bozikov, V., Gitt, A. K., Jermendy, G., Campaigne, B. N., Kerr, L., Milicevic, Z., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1671 · Cited by 351
Mudaliar, S. R., Lindberg, F. A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., & Henry, R. R. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1501 · Cited by 276
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Perkins, B. A., Welsh, J. B., Willi, S. M., et al. (2011) · Diabetes Care · doi:10.2337/dc11-1248 · Cited by 118
Hompesch, M., Muchmore, D. B., Morrow, L., Ludington, E., & Vaughn, D. E. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0117 · Cited by 25
Self-citation
Cited by
Heise, T., Pieber, T. R., Danne, T., Erichsen, L., & Haahr, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0514-8 · Cited by 182
Bowering, K., Case, C., Harvey, J., Reeves, M., Sampson, M., Strzinek, R., Bretler, D.-M., Bang, R. B., & Bode, B. W. (2017) · Diabetes Care · doi:10.2337/dc16-1770 · Cited by 119
“However, there remains an unmet need for insulin analogs with an even faster onset of action than rapid-acting insulin analogs, which could potentially achieve better PPG control (7,8).”
BackgroundBorot, S., Franc, S., Cristante, J., Penfornis, A., Benhamou, P.-Y., Guerci, B., Hanaire, H., Renard, E., Reznik, Y., Simon, C., et al. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814543946 · Cited by 47
Seaquist, E. R., Blonde, L., McGill, J. B., Heller, S. R., Kendall, D. M., Bumpass, J. B., Pompilio, F. M., & Grant, M. L. (2020) · Diabetic Medicine · doi:10.1111/dme.14202 · Cited by 30
Wadwa, R. P., Laffel, L. M., Franco, D. R., Dellva, M. A., Knights, A. W., & Pollom, R. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14849 · Cited by 24
“There remains a need to continue to develop more rapid-acting insulin formulations with a time-action profile to better match that of endogenous insulin secretion to provide effective glycaemic control without risk of hypoglycaemia and hyperglycaemia.(11,12) Ultra-rapid lispro (URLi) is an insulin lispro formulation w…”
Background
Metadata
- Authors
- Heinemann, L., & Muchmore, D. B.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2012-07
- Volume
- 6
- Issue
- 4
- Pages
- 728-742
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2112851047
- Cited by
- 89
- References
- 8
- Type
- conference abstract
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ultrafast-Acting Insulins: State of the Art. https://app.cochat.ai/papers/10.1177/193229681200600402
- The paper
- Heinemann, L., & Muchmore, D. B. (2012). Ultrafast-Acting Insulins: State of the Art. Journal of Diabetes Science and Technology. https://doi.org/10.1177/193229681200600402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.